Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 42,120,348
  • Shares Outstanding, K 253,890
  • Annual Sales, $ 2,489 M
  • Annual Income, $ 263,480 K
  • 36-Month Beta 1.61
  • Price/Sales 16.08
  • Price/Cash Flow 150.27
  • Price/Book 19.51

Price Performance

See More
Period Period Low Period High Performance
1-Month
146.21 +13.47%
on 02/09/18
174.96 -5.18%
on 02/01/18
-0.68 (-0.41%)
since 01/23/18
3-Month
136.50 +21.54%
on 12/07/17
174.96 -5.18%
on 02/01/18
+18.86 (+12.83%)
since 11/22/17
52-Week
84.62 +96.05%
on 02/24/17
174.96 -5.18%
on 02/01/18
+80.17 (+93.51%)
since 02/23/17

Most Recent Stories

More News
Vertex Initiates First Phase 3 Study of VX-659, Tezacaftor and Ivacaftor as a Triple Combination Regimen for People with Cystic Fibrosis

---Study designed to support submission of New Drug Application in the U.S. based on 4-week primary efficacy endpoint and 12-week safety data-

VRTX : 165.90 (+5.27%)
The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex

The Zacks Analyst Blog Highlights: Amgen, TOTAL, Marriott, PG&E and Vertex

PCG : 41.14 (+2.62%)
VRTX : 165.90 (+5.27%)
TOT : 58.38 (+1.48%)
AMGN : 186.67 (+2.31%)
MAR : 142.17 (+1.12%)
Top Analyst Report for Amgen, TOTAL S.A. & Marriott

Top Analyst Report for Amgen, TOTAL S.A. & Marriott

PCG : 41.14 (+2.62%)
VRTX : 165.90 (+5.27%)
TOT : 58.38 (+1.48%)
AMGN : 186.67 (+2.31%)
MAR : 142.17 (+1.12%)
ED : 77.63 (+2.43%)
Look for Shares of Vertex Pharm to Potentially Pullback after Yesterday's 1.09% Rise

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $157.16 to a high of $160.90. Yesterday, the shares gained 1.1%, which took the trading range above the 3-day high of...

VRTX : 165.90 (+5.27%)
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval

Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.

XOMA : 26.16 (+3.20%)
CNCE : 21.75 (+2.59%)
VRTX : 165.90 (+5.27%)
EXEL : 29.51 (+1.41%)
FDA Approves SYMDEKO(TM) (tezacaftor/ivacaftor and ivacaftor) to Treat the Underlying Cause of Cystic Fibrosis in People Ages 12 and Older with Certain Mutations in the CFTR Gene

--- SYMDEKO to begin shipping to pharmacies this week -

VRTX : 165.90 (+5.27%)
SmarTrend Watching for Potential Rebound in Shares of Vertex Pharm After 1.75% Loss

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $148.16 to a high of $153.36. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $151.35...

VRTX : 165.90 (+5.27%)
The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services

The Zacks Analyst Blog Highlights: Wells Fargo, Caterpillar, Schlumberger, Vertex and Republic Services

WFC : 59.17 (+0.61%)
CAT : 162.41 (+2.23%)
RSG : 66.40 (+1.47%)
VRTX : 165.90 (+5.27%)
SLB : 66.50 (+2.37%)
Top Stock Reports for Wells Fargo, Caterpillar & Schlumberger

Top Stock Reports for Wells Fargo, Caterpillar & Schlumberger

ROP : 281.14 (+0.55%)
WFC : 59.17 (+0.61%)
RSG : 66.40 (+1.47%)
CAT : 162.41 (+2.23%)
VRTX : 165.90 (+5.27%)
SLB : 66.50 (+2.37%)
REGN vs. ALXN: Which Stock is Poised for Better Q4 Earnings?

Let's take a look at which of these biotech companies, Alexion (ALXN) or Regeneron (REGN) has an edge ahead of their Q4 release.

CELG : 95.61 (+1.95%)
VRTX : 165.90 (+5.27%)
REGN : 323.86 (+2.55%)
JUNO : 86.58 (+0.02%)
SNY : 40.13 (+0.70%)
ALXN : 118.93 (+3.79%)
BIIB : 292.78 (+2.80%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 171.21
1st Resistance Point 168.55
Last Price 165.90
1st Support Level 160.67
2nd Support Level 155.45

See More

52-Week High 174.96
Last Price 165.90
Fibonacci 61.8% 140.45
Fibonacci 50% 129.79
Fibonacci 38.2% 119.13
52-Week Low 84.62

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.